Nature

Histone deacetylase inhibitor FK228 suppresses the Ras–MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma

Histone deacetylase (HDAC) inhibitors are expected to be effective for refractory cancer because their mechanism of action differs from that of conventional antineoplastic agents. In this study, we ...
Yahoo Finance

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor more potent than other KRAS G12D inhibitors in preclinical models VS-7375, when combined with cetuximab, demonstrated strong tumor ...
Seeking Alpha

Erasca, Inc.: Carving A Different Niche In RAS Signaling

Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company’s lead program, ...
BioWorld

RMC-7977 targets RAS/MAPK pathway and sensitizes AML cells

The effective targeting of RAS-mutant acute myeloid leukemia (AML) still remains a challenge; RAS mutations are tied to relapse to targeted therapy, such as resistance to FLT3 inhibitors due to the ...
Business Wire

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025 Potential U.S. commercial ...
Nature

Pathway discovery: The road to Ras and MAP kinase

In 1980 I was recruited to the Institute of Cancer Research (ICR) by its new director, Robin Weiss. After seven years as a postdoctoral fellow, at last I was a tenure-track faculty member and anxious ...
ascopubs.org

Molecular alterations in the Ras-Raf-Erk (MAPK) pathway in metastatic hormone receptor positive (HR+)/HER2- breast cancer: Incidence and impact on clinical outcomes.

Comparison of tissue genotyping (TG) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic breast cancer (MBC). This is an ...
ascopubs.org

Molecular characterization of the Ras-MAPK pathway in metastatic breast cancer.

Uncovering the differential impact of ESR1 and PIK3CA codon variants on the clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS).
KTLA

Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid Tumors

Promising preliminary monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors, which had favorable safety, tolerability, and efficacy profiles that support ...
BioWorld

Verastem and Genfleet establish discovery and development collaboration for RAS pathway-driven cancers

Verastem Oncology Inc. has entered into a discovery and development collaboration with Genfleet Therapeutics (Shanghai) Ltd. to advance three oncology discovery programs targeting RAS pathway-driven ...
Yahoo Finance

BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition

SOUTH SAN FRANCISCO, Calif. and BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on ...